Anti-cd166 Probody-drug Conjugate Cx-2009
Anti-cd166 Probody-drug Conjugate Cx-2009 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-cd166 Probody-drug Conjugate Cx-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-Anti-cd166 Probody-drug Conjugate Cx-2009: A Trial to Find Safe and Active Doses of an Investigational Drug Anti-cd166 Probody-drug Conjugate Cx-2009 for Patients With Selected Solid Tumors).
| Trade Name | Anti-cd166 Probody-drug Conjugate Cx-2009 |
| Generic | CX-2009 |
| CX-2009 Other Names | Anti-cd166 probody-drug conjugate cx-2009, Praluzatamab ravtansine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-cd166 Probody-drug Conjugate Cx-2009
